Bristol Myers Squibb patents CD80/PD-L1 and/or PD-1/PD-L1 interaction inhibitors Aug. 4, 2021 No Comments
FDA authorizes IND for phase I testing of Sorrento's CD38 DAR-T cell therapy candidate Aug. 3, 2021 No Comments
Phase I trial evaluates iPSC-derived CAR T-cell therapy FT-819 for CD19+ malignancies Aug. 3, 2021 No Comments
Bristol Myers Squibb patents CD80/PD-L1 and/or PD-1/PD-L1 interaction inhibitors Aug. 3, 2021 No Comments
U.K. MHRA clears initiation of first-in-human study of HMBD-001 in advanced cancers Aug. 2, 2021 No Comments
RSS